# KLOW Peptide Results in the Research Literature — Skin-Matrix Lens > KLOW results drawn from the single-component research literature: GHK-Cu skin-matrix outcomes, BPC-157 tissue-repair findings, TB-500/thymosin beta-4 wound results and KPV anti-inflammatory data. No blend-level trial exists; every result is per-component. What each component has produced in controlled studies — skin-matrix arm first. The blend has no results of its own. ## In plain English KLOW results means the results of the four individual compounds that make up KLOW — because no one has run a controlled trial on the four-peptide blend. GHK-Cu is the skin-matrix lead and its results are the most directly relevant to what a skin-oriented researcher might care about. BPC-157 and thymosin beta-4/TB-500 have the most dramatic wound and tendon repair numbers. KPV has the most targeted anti-inflammatory data. Together they make a plausible case for a complementary four-arm stack; what they do not yet make is a proven case for the combination. ## GHK-Cu skin-matrix results The headline skin result for GHK-Cu is a placebo-controlled clinical comparison: topical GHK-Cu increased collagen production in 70% of treated women versus 50% for topical vitamin C and 40% for retinoic acid [4]. This is a direct human comparison of efficacy on a collagen synthesis endpoint, from a peer-reviewed review of human cosmetic trial data. At the transcriptomic level: GHK modulates approximately 31.2% of human protein-coding genes at a 50%-or-greater change threshold in fibroblasts, with the strongest signals on extracellular-matrix remodeling, antioxidant defense, DNA repair and anti-inflammatory programs [5]. GHK-Cu stimulates synthesis of collagen, dermatan sulfate, chondroitin sulfate and the proteoglycan decorin [4]. A 2025 review characterizes GHK as the best-supported anti-wrinkle peptide available topically, synthesizing the evidence base and the delivery limitations [11]. A 2024 mechanistic study found GHK reverses age-related fibrosis by modulating myofibroblast function [12] — relevant to the progressive collagen stiffening of aged skin and connective tissue. For hair: a placebo-controlled 6-month trial in 45 men with androgenetic alopecia found a GHK-containing topical (combined with 5-aminolevulinic acid) produced statistically significant hair count increases versus placebo (+52.6 and +71.5 hairs vs +9.6, p<0.05) [9]. The formulation contains a second active ingredient; GHK-alone attribution is not established by this study. Skin penetration: copper applied as GHK-Cu penetrates dermatomed human skin with 136.2 ± 17.5 μg/cm² permeating over 48 hours and a 97 ± 6.6 μg/cm² dermal depot [8]. This establishes topical delivery as viable and quantifies the depot-forming behavior. ## TB-500/thymosin beta-4 wound results The most reproducible result in the wound-closure component literature: topical or intraperitoneal thymosin beta-4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days versus saline in a rat full-thickness wound model, increased wound contraction (at least 11% by day 7), raised collagen deposition and angiogenesis, and stimulated keratinocyte migration 2 to 3-fold at as little as 10 pg [1]. These are full-length native thymosin beta-4 findings. The TB-500 fragment shares the LKKTET actin-binding motif but most foundational efficacy data are for the full-length protein. The 2026 sports medicine review of unapproved musculoskeletal peptides (including thymosin beta-4/TB-500 and BPC-157) finds animal-model data promising but characterizes human safety evidence as scarce [7]. ## BPC-157 tissue-repair results BPC-157 accelerated healing of a fully transected rat Achilles tendon across biomechanical, functional, microscopic and macroscopic measures, and stimulated tendocyte (tendon cell) outgrowth in vitro, across doses from 10 μg down to 10 pg per rat administered intraperitoneally once daily [2]. The dose-response extended to picogram doses, a notable sensitivity. In a 2024 human pilot of interstitial cystitis patients, BPC-157 produced complete symptom resolution in 10 of 12 participants and approximately 80% improvement in the remaining two, with a 5/5 Global Response Assessment and no adverse events [13]. This is an uncontrolled pilot — no placebo arm, small n — but it is the clearest human efficacy signal yet published for BPC-157 in any indication. A 2025 first-in-human IV safety pilot reported 10 mg and 20 mg IV BPC-157 was well tolerated in two healthy adults with no adverse events and no measurable changes in safety biomarkers [6]. This is not an efficacy study. ## KPV anti-inflammatory results KPV reduced NF-kappaB and MAPK activation and pro-inflammatory cytokine secretion (TNF-alpha, IL-6, IL-1beta) at nanomolar concentrations in human intestinal epithelial and immune cells in vitro [3]. In DSS- and TNBS-induced colitis mouse models, oral KPV at 100 micromolar in drinking water reduced colitis severity [3]. The PepT1-mediated uptake into inflamed intestinal epithelium provides the mechanistic basis for the gut-targeting effect. No controlled KPV monotherapy trial has reached regulatory approval. These results are from cells and mouse models. ## The combination result There is no combination result. No controlled study has placed the four-peptide KLOW blend in any experimental model — rodent, cell or human — and measured an outcome against a control. The [klow results](/results) available in the literature are, in full, the per-component findings documented above. This blank is the honest state of the record as of mid-2026. --- A letterpress reading-record that presses each of the four KLOW components against its own cited studies, leaves the absent blend trial as the single most prominent blank on the page, and operates no clinic, counter, or dispensary behind the impressed type.